ArticleFuture science OA2025
Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare several laboratory results, including liver function, lipid metabolism (HDL), pulmonary function, and hematological parameters among COVID-19 recovered patients who were divided into two groups (asymptomatic/mild vs. moderate/severe).
methodThe sample consisted of patients matched by age and gender. These patients were divided into two groups. The first group consisted of mild or mild cases, and the second group included moderate and severe cases, classified based on their need for oxygen. Blood samples were collected from all participants, and analyses for complete blood count, liver function markers, kidney function markers, and lipid profiles were conducted at the Health Center of Jordan University of Science and Technology and King Abdullah University laboratories.
resultsThe analysis revealed Significant differences were noted in ALT (p = 0.002), DBC (p = 0.005), HDL (p = 0.035), Notably, the Forced Vital Capacity (FVC) showed a significant difference (F = 6.292, p = 0.012). The FEV1/FVC ratio was also highly significant (F = 45.054, p = 0.000).
conclusionIn this descriptive cohort study, the results indicating that specific biomarkers, such as elevated WBC and liver enzymes, are significantly associated with severe post-COVID outcomes. These findings highlight the systemic impact of the disease in severe cases, affecting multiple or one organ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.